- Home
- E vs TAK Comparison
E vs TAK Comparison
Compare E & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- E
- TAK
- Stock Information
- Founded
- E 1953
- TAK 1781
- Country
- E Italy
- TAK Japan
- Employees
- E N/A
- TAK N/A
- Industry
- E Oil & Gas Production
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- E Energy
- TAK Health Care
- Exchange
- E Nasdaq
- TAK Nasdaq
- Market Cap
- E 49.9B
- TAK 43.9B
- IPO Year
- E 1995
- TAK N/A
- Fundamental
- Price
- E $28.93
- TAK $13.29
- Analyst Decision
- E Buy
- TAK
- Analyst Count
- E 6
- TAK 0
- Target Price
- E $39.60
- TAK N/A
- AVG Volume (30 Days)
- E 261.6K
- TAK 1.5M
- Earning Date
- E 10-25-2024
- TAK 10-31-2024
- Dividend Yield
- E 7.51%
- TAK 4.79%
- EPS Growth
- E N/A
- TAK 49.73
- EPS
- E 0.85
- TAK 1.27
- Revenue
- E $102,822,886,419.00
- TAK $31,732,209,416.00
- Revenue This Year
- E N/A
- TAK $4.41
- Revenue Next Year
- E N/A
- TAK $1.09
- P/E Ratio
- E $16.53
- TAK $21.08
- Revenue Growth
- E N/A
- TAK 9.43
- 52 Week Low
- E $28.74
- TAK $12.58
- 52 Week High
- E $34.30
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- E 36.07
- TAK 32.35
- Support Level
- E $28.79
- TAK $13.50
- Resistance Level
- E $30.11
- TAK $13.75
- Average True Range (ATR)
- E 0.34
- TAK 0.16
- MACD
- E -0.08
- TAK -0.02
- Stochastic Oscillator
- E 9.18
- TAK 7.28
About E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2023, Eni held reserves of 6.4 billion barrels of oil equivalent, 48% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plentitude, which it will likely list publicly at some point.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.